Abstract: An integrated circuit to drive a plurality of fluid actuation devices includes a plurality of contact pads, a plurality of pulldown devices, and control logic. The plurality of contact pads include a first contact pad and a second contact pad. Each of the pulldown devices is electrically coupled to a corresponding contact pad. The control logic enables at least a portion of the pulldown devices in response to both a logic low signal on the first contact pad and a logic low signal on the second contact pad.

Abstract: The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.

Abstract: A method, apparatus, and computer readable storage medium perform oilfield-wide optimization in a field with a plurality of wells, with each well including a well flow rate management mechanism controlled by an associated well controller. In a central controller, a network simulation model functioning as a proxy of the field is accessed to determine an optimal allocation solution for the field, and a well-specific control signal is generated for each of the plurality of wells based upon the determined optimal allocation solution. The well-specific control signal for each of the plurality of wells is communicated to cause the associated well controller to control a flow rate management parameter associated with the well flow rate management mechanism for the well.

Abstract: Disclosed herein are compositions and methods for construction of chromatin immunoprecipitation (ChIP) sequencing libraries involving the use of Tn5 tagmentation, splint ligation and/or single-stranded DNA ligation.

Abstract: Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells. The aptamers can be used as a therapeutic agent by itself or in combination with a small molecule by forming a conjugate with the small molecule. Targeted delivery of the small molecule can be achieved by such conjugates. Also disclosed are methods of treating a subject suffering from cancer by administering an effective amount of the aptamer or the aptamer-small molecule conjugate to the subject.

Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of antiviral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.

Abstract: A method, apparatus, and program product perform lift optimization in a field with a plurality of wells, with each well including an artificial lift mechanism controlled by an associated well controller. In a central controller, a network simulation model functioning as a proxy of the field is accessed to determine an optimal allocation solution for the field, and a well-specific control signal is generated for each of the plurality of wells based upon the determined optimal allocation solution. The well-specific control signal for each of the plurality of wells is communicated to the associated well controller to cause the associated well controller to control a lift parameter associated with the artificial lift mechanism for the well.

Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of antiviral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.

Abstract: The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.

Abstract: In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.

Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of anti-viral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.

Abstract: A method and system for estimating energy consumption of a utility population includes organizing the utility population comprising energy consumers into a plurality of groups. Next, a distribution of energy consumption against the plurality of groups may be calculated. Subsequently, statistically representative groups based on the energy distribution and the plurality of groups may be determined. Data is then collected from the statistically representative groups at predefined intervals from a communications network. Energy consumption of the utility population may then be estimated based on the data collected from the statistically representative groups. The communications network comprises an advanced metering infrastructure (AMI) network.

Abstract: A method and system for managing an energy supply of a utility provider include calibrating one or more climate controlled spaces for a controller. The calibrating may include calculating a heating/cooling ratio for the one or more climate controlled spaces. After this calibration occurs, the system may determine if an energy supply surplus exists. If an energy supply surplus exists, then the system may start using the one or more climate controlled spaces as energy sinks for expending energy according to the heating/cooling ratio. The system may also determine if an energy supply deficit exists and if an energy supply deficit exists, then the system may start using the one or more climate controlled spaces as energy “sources,” in which a direct load control algorithm is used to reduce energy consumption by the one or more climate controlled spaces.

Abstract: In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.

Abstract: Provided herein are, inter alia, antiviral recombinant nucleic acid compositions and methods of using the same. The recombinant nucleic acid compositions include nucleic acids encoding antiviral polycistronic RNAs, which are capable of inhibiting viral replication. The antiviral recombinant nucleic acid compositions provided herein are therefore particularly useful for therapeutic applications such as combinational HIV-1 gene therapy.

Abstract: A method, apparatus, and computer readable storage medium perform oilfield-wide optimization in a field with a plurality of wells, with each well including a well flow rate management mechanism controlled by an associated well controller. In a central controller, a network simulation model functioning as a proxy of the field is accessed to determine an optimal allocation solution for the field, and a well-specific control signal is generated for each of the plurality of wells based upon the determined optimal allocation solution. The well-specific control signal for each of the plurality of wells is communicated to cause the associated well controller to control a flow rate management parameter associated with the well flow rate management mechanism for the well.

Abstract: In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.

Abstract: In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.

Abstract: A method, apparatus, and program product perform lift optimization in a field with a plurality of wells, with each well including an artificial lift mechanism controlled by an associated well controller. In a central controller, a network simulation model functioning as a proxy of the field is accessed to determine an optimal allocation solution for the field, and a well-specific control signal is generated for each of the plurality of wells based upon the determined optimal allocation solution. The well-specific control signal for each of the plurality of wells is communicated to the associated well controller to cause the associated well controller to control a lift parameter associated with the artificial lift mechanism for the well.

Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of antiviral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.